IDELVION® - Key Publications | CSL Behring Medical Affairs

Have a Question? Use Our New Chat Feature! Chat with our Medical Information Specialists by clicking on the Chat with us now available in the lower right corner of this screen.

Product Information	Educational Materials	Conferences and Events	Key Publications

Hemophilia B Publications

Safety and Efficacy of Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Previously Untreated Patients with Hemophilia B

^{Tap Image to view Graphical Abstract}

R. Lemons et al. Thieme 2024
Request | Ask a Question | View Article

Long-acting recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in children. Results of a phase 3 trial

G. Kenet, Chambost H.. J. Thrombosis and Hemostasis, 2016
Request | Ask a Question | View Article

Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial

E. Santagostino, U. Martinowitz, et al. Blood, April 2016
Request | Ask a Question | View Article

Efficacy and safety of long-acting recombinant fusion protein linking factor IX with albumin in haemophilia B patients undergoing surgery

E. Negrier et al. Haemophilia 2016
Request | Ask a Question | View Article

Hemophilia B Posters

Efficacy and Safety of Recombinant Factor IX Fusion Protein (rIX-FP) in Previously Untreated Patients with Hemophilia B

View Poster

Please see full prescribing information for IDELVION

Safety and efficacy of recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in pediatric patients with hemophilia B: A review of results from phase 3 trial studies

View Poster

Please see full prescribing information for IDELVION